Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma
Cancer Genomics - Proteomics · 2026-07 · 23 (4) · 714-729
DOI: 10.21873/cgp.20598 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Genomics - Proteomics, online erschienen am 29.06.2026. Verfasst von Jeng-Shiun DU und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. Hauptthemen laut MEDLINE: Deoxycytidine, Cholangiocarcinoma, Bile Duct Neoplasms, Biomarkers, Tumor. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
- Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
- Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
- Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
- Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.; 1025017@kmuh.org.tw 1095056@kmuh.org.tw.
- Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.; 1025017@kmuh.org.tw 1095056@kmuh.org.tw.
Zitieren
APA
DU, J. S., Moi, S. H., Hung, Y. H., Chang, Y. H., Chang, S. J., Wang, M. H., Wang, H. C., Luo, C. W., Yang, Y. C., Chen, L. T., & Pan, M. R. (2026). Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma. Cancer Genomics - Proteomics, 23(4), 714-729. https://doi.org/10.21873/cgp.20598
Vancouver
DU JS, Moi SH, Hung YH, Chang YH, Chang SJ, Wang MH, et al. Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma. Cancer Genomics - Proteomics. 2026;23(4):714-729. doi:10.21873/cgp.20598
BibTeX
@article{DU2026,
author = {DU, Jeng-Shiun and Moi, Sin-Hua and Hung, Yu-Hsuan and Chang, Ya-Hui and Chang, Shu-Jyuan and Wang, Min-Hong and Wang, Hui-Ching and Luo, Chi-Wen and Yang, Yu-Ci and Chen, Li-Tzong and Pan, Mei-Ren},
title = {Transcriptomic Profiling Identifies Higher DOT1L Expression as a Candidate Biomarker for a Positive Response to Gemcitabine in Cholangiocarcinoma},
journal = {Cancer Genomics - Proteomics},
year = {2026},
volume = {23},
number = {4},
pages = {714--729},
doi = {10.21873/cgp.20598}
}
EUVIMED